MORGAN STANLEY: AVR position timeline
Available 13F reports, 13D and 13G stakes and each Form 3, 4 and 5 line of MORGAN STANLEY on AVR, newest first. How the timeline and the estimate are built.
MORGAN STANLEY held 124,358 AVR shares at 2026-06-30 per its 13F-HR filed 2026-08-13.
the latest 13F is the newest step
- period ended2026-06-3013F 124,358 sharesChange vs previous 13F -41,000 shares
<0.01% of the 13F portfolio, value $1,224,926.
13F-HR 0000895421-26-000243 filed by MORGAN STANLEY
Filed (acceptance time not in the bulk data set), ingestedAcceptance time not in the bulk data set (spec §4.2).
- period ended2026-03-3113F 165,358 sharesChange vs previous 13F +84,980 shares
<0.01% of the 13F portfolio, value $917,736.
13F-HR 0000895421-26-000183 filed by MORGAN STANLEY
Filed (acceptance time not in the bulk data set), ingestedAcceptance time not in the bulk data set (spec §4.2).
- period ended2025-12-3113F/A 80,378 sharesChange vs previous 13F +6,770 shares
<0.01% of the 13F portfolio, value $401,086.
13F-HR/A 0000895421-26-000187 filed by MORGAN STANLEY
Filed (acceptance time not in the bulk data set), ingestedAcceptance time not in the bulk data set (spec §4.2).
- period ended2025-09-3013F/A 73,608 sharesChange vs previous 13F +2,181 shares
<0.01% of the 13F portfolio, value $331,237.
13F-HR/A 0000895421-26-000186 filed by MORGAN STANLEY
Filed (acceptance time not in the bulk data set), ingestedAcceptance time not in the bulk data set (spec §4.2).
- period ended2025-06-3013F 71,427 sharesChange vs previous 13F +23,727 shares
<0.01% of the 13F portfolio, value $270,708.
13F-HR 0000895421-25-000499 filed by MORGAN STANLEY
Filed (acceptance time not in the bulk data set), ingestedAcceptance time not in the bulk data set (spec §4.2).
- period ended2025-03-3113F 47,700 sharesChange vs previous 13F not available
<0.01% of the 13F portfolio, value $173,629.
13F-HR 0000895421-25-000381 filed by MORGAN STANLEY
Filed (acceptance time not in the bulk data set), ingestedAcceptance time not in the bulk data set (spec §4.2).